Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

297 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

198 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

164 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We deliver data for life > Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions. MALDI Imaging, ADME analysis, Mass Spectrometry Imaging, Preclinical services, Molecular Imaging, Biodistribution, …

156 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

215 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Next-Generation Synthetic Macrocycle Drug Discovery Our mission is to unlock drug discovery for challenging and currently undruggable pharmaceutical targets, which leave many diseases without effective treatments. The Pure-DEL platform enables, for the first time, the evaluation of billions of synthetic macrocycles with drug-like properties in a single experiment, with the goal of unlocking new disease targets and enabling orally available medicines. * Pure-DEL Technology: https://doi.org/10.1126/science.adn3412 * ETH News Article: https://ethz.ch/en/news-and-events/eth-news/news/2024/09/new-pharmaceutically-active-substances-from-billions-of-newly-combined-molecules.html * Drug Target Review: https://www.drugtargetreview.com/article/153843/unlocking-a-new-molecular-space-in-rapid-drug-discovery/ Drug discovery, DNA-Encoded Libraries, Macrocycles, 'Undruggable' Targets, Oral drug discovery, and Intracellular Targets

58 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

miRNA-enhanced Extracellular Vesicles Therapeutics ConvEyXO, founded in 2019 by veterans of pharma industry, builds a specialized technology platform to convey exosome-based therapeutics to the market. The company is developing is therapeutic portfolio in the field of fibrosis and chronic inflammatory disorders. The rapid development of the company is the result of collaborations with partners with a demonstrated track record in healthtech and biotech fields manufacturing, process development, upstream, downstream, extracellular vesicles, exosomes, therapeutics, cargo, Loading, 4D, and exosomes

111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating Biologics Discovery with Advanced Cell Based Functional Assays, Yeast & Mammalian Display Platforms, Ranomics is a CRO partner in engineering better biologics, faster. With expertise in custom cell-based functional and screening assays, yeast display and mammalian display, we are a valuable parter in protein engineering, antibody engineering, antibody discovery and custom biologics development. Disease Prediction, Human Genetics, Genome Sequencing, biotechnology, synthetic biology, protein engineering, genomics, drug discovery, mutagenesis, gene synthesis, dna variant library, antibody, DNA, Protein, Research, Contract Research, Biotechnology, Catalysis, Bioprocess Engineering, Biologic Manufacturing, Biochemistry, and Epitope Mapping

124 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space. synthetic biology, RNA design, immunotherapy, covid-19, cancer, and mRNA therapy

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBioTM Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications.

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

587 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

164 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reshaping rhBMP-2 Perspectives Relieving suffering and improving quality of life with next-generation orthobiologics. Regenerative Medicine, Biomaterials, Medical devices, Drug delivery, biotechnology, BMP2, Programmed Drug Release, and Instructive Tissue Scaffolds

203 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

183 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

PepKon is a French biotech founded in 2022, built on more than a decade of academic research. The company develops first-in-class peptide therapeutics for incurable cancers.

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sharp understanding of the hardest things At Sagacity Health, we discover new horizons in oncology by merging Agentic AI with Biotech to decode the secret world inside tumors - turning unseen ecosystems into the next frontier of precision therapeutics. Our main objective is to bridge groundbreaking science, clinical partnerships, and industrial-scale innovation to bring first-in-class therapies from lab to patient. This is not just drug development; it is a paradigm shift in how we fight cancer.

108 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle

260 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology

Life, reimagined. Constructive Bio designs and manufactures proteins with chemistries that don't exist in nature. By rewriting the genetic code, we give cells access to entirely new chemical building blocks, then scale what we find into medicines and materials that couldn't exist before. Our BioForge platform turns advanced molecular designs into manufacturable reality: complex peptides, site-specific conjugates, covalent biologics, and oral therapeutics that conventional synthesis cannot reliably produce. Constructive and its partners shift the question from "can we make this?" to "what should we make next?". Synthetic Biology, Genome engineering, Biopolymers, Protein engineering, Therapeutics, Biomanufacturing, and Genetic code expansion

59 similar entities Type: Startup Activities: it services deeptech Technologies: Synthetic Biology

Transforming protein biologics with groundbreaking high-throughput protein engineering. Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biology and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, …

141 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech Company 100% Focused on Pediatric Cancer Drug Development A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Medicine Maker celebrates the people, processes and vision that bring new drugs and biologics to market. The development and manufacture of new drugs and biological medicines draws on the talent, passion and experience of a wide range of professionals. The goal of The Medicine Maker is to bring this group into the limelight and, in doing so, to integrate the entire process, from the registration of an Investigational New Drug (IND) or Biologics License Application (BLA) through to the market launch of new therapies, and beyond. pharmaceutical , biopharmaceutical, bioprocess, upstream, downstream, formulation, drug delivery, and dosage form

129 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Your Science-Driven Partner in Small Molecules, Biologics & Nucleic Acids From Molecule to Medicine—Your Science-Driven Partner in Small Molecules, Biologics, and Nucleic Acids Crystal Pharmatech, founded in 2010, is a global contract research organization with over 300 employees and four R&D centers in New Jersey (USA), San Francisco (USA), Toronto (Canada), and Suzhou (China). Collectively, these sites provide integrated support for pharmaceutical and biotechnology companies worldwide. Our capabilities span three specialized platforms: in small molecules, we offer API solid-state research and crystallization, preformulation, formulation development, and GMP manufacturing and supply; through Crystal Bio Solutions, we deliver bioanalytical and biomarker testing, …

60 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Nature's pharmacy, re-engineered Biomia is a synthetic biology company developing a pipeline of plant-inspired natural or new-to-nature therapeutic products to address the unmet medical needs in pain, addiction, and mental health conditions.

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Disruptive Solutions, Healthier Futures FOSCA BioTech is developing disruptive technologies to simultaneously remove multiple cancer-related molecules, transforming cancer treatment approaches with unprecedented precision.

59 similar entities Type: Startup Activities: deeptech biotech

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

261 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Cell rejuvenation to rewind age driven diseases Shift Bioscience has built the best-in-class target discovery platform for cell rejuvenation, identifying an initial siRNA program in liver fibrosis with first-in-class and expansion potential. Cambridge (UK) based with a team spanning Longevity, virtual cells, siRNA and liver disease, Shift is seeking strategic partnerships that accelerate the first medicines for both healthspan and lifespan. longevity, reprogamming, machine learning, aging clocks, transcriptomics, and virtual cell

62 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: A.I. Synthetic Biology

We generate preclinical data that accelerates drug development. Modern research without blindspots, through a solution that unveils important insights in preclinical trials. Biotechnology , Drug development, Machine learning, Artificial Intelligence, Deep tech, Preclinical research, Animal welfare, and 3R

83 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

749 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

145 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

CONNECT COLLABORATE EVOLVE Biotrains is a global leader in providing business conferences, training, managed events, and consulting services tailored to the Pharmaceutical, Biotech, Healthcare, and Medical Device industries. We specialize in delivering world-class content and expert knowledge to empower professionals and give organizations a competitive edge. Our events cover technical areas such as Bioprocess Development, Drug Discovery, Diagnostics, Personalized Medicine, Medical Devices, and Healthcare. With a focus on innovation and continuous learning, Biotrains is dedicated to fostering success in both business and academia. Event , Conference, Trainnig, Pharmaceutical, Biotechnology, Home Healthcare, Pharma IT, drugformulation, and workshops

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

485 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

296 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics. Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

67 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

103 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Enabling next generation medicines. A comprehensive platform and product suite for advanced therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

187 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

140 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Redefining the future of drug development with a non-conventional biopharmaceutical model Landmark BioVentures is an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies. Anchored by foundational science, LBV uncovers hidden gems with unrealized therapeutic potential by connecting non-obvious dots and taking a strategically-focused active hands-on approach with each nexus company. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments, to streamline drug development, focusing on holistic value creation and capture. drug development , …

136 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Drug discovery with cutting-edge AI technology We’re pioneering the use of AI and shaping the future in drug discovery, significantly cutting costs and development times. Our unique AI algorithms have generated novel drug candidates and identified enhancements for existing therapies more efficiently than traditional methods, setting us apart in the competitive landscape. Artificial Intelligence, Data Science, Health, Medicines, and Drug development

152 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies.

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to discovering and advancing novel therapeutics that halt or slow the ageing process for healthier lives Genflow Biosciences plc (LON: GENF) (OTCQB: GENFF) is an emerging leader in the field of longevity research with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the aging process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. Managed by an experienced team with decades of experience in the pharmaceutical and …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

hVIVO - Making Innovation Possible Venn Life Sciences is now hVIVO. Making Innovation Possible hVIVO plc (Ticker: HVO) is a science‐led early‐phase drug development company purpose‐built to meet the growing complexity of modern clinical research. The Company operates an integrated early‐phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‐ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials. With industry‐leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other …

45 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

307 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

435 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.

83 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

460 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Pharmacoidea Ltd. is a Hungarian biotech company specialized in drug discovery, pharma- and nutraceutical development. PHARMACOIDEA Ltd. is an innovation-driven Hungarian biotech company specializing in drug discovery, pharma- and nutraceutical development, and advanced therapeutic solutions. Our research portfolio spans from next-generation nutraceuticals to molecularly-targeted drug delivery, biomarker discovery, and experimental therapeutics against SARS-CoV-2 infection. Our multidisciplinary team of scientists is dedicated to translating breakthrough research into real-world medical applications, addressing unmet medical needs with cutting-edge molecular pharmacology, and biotechnology tools. Pharmacoidea's proprietary brain delivery technology enables the transport of macromolecular agents across the blood-brain barrier, holding significant promise for Alzheimer’s …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

127 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

505 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

281 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Discovering the true signals of disease to power life-changing medicines. 90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that with better, faster drug target discovery powered by the Newfoundland founder effect. Biotechnology and Drug Discovery

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

422 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Zerion Pharma is a pharmaceutical company transforming the landscape for formulation of poorly soluble drugs Zerion is a pharmaceutical company transforming the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas. We are focused on improving existing drug products by building an internal pipeline, while partnering with originators to enable their early stage drug molecules, striving to improve the lives of patients around the world. Pharmaceuticals, Formulation, and Drug delivery

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Breaking Biology Free Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A drug-discovery company focused on oncology, with a unique and powerful combination of expertise that sets us apart. Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I.

Pioneering the development of microbiome-based therapies using proprietary tools for their design and production. PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This …

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your CDMO for Life-Changing Therapies. In the complex world of biomanufacturing, technical precision is the standard, but human commitment is the difference. At LFB Biomanufacturing, we understand that a biological breakthrough is more than a formula or a process : it is a promise waiting to be kept. We see ourselves as the human link between your science and patient's story. We know that moving a molecule from the lab to the real world requires more than just high-end equipment. It requires dedicated expertise that turns biological breakthroughs into a patient's reality. When you partner with us, you are not …

56 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

265 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating Life Sciences InSilicoTrials is a leading technology company revolutionizing drug development through AI-powered simulation. Our platform provides pharmaceutical and biotech companies with access to a vast library of computational models, enabling them to simulate drug interactions, predict outcomes, and accelerate the discovery of new treatments. By leveraging digital patient twins and advanced AI algorithms, we offer a more efficient and cost-effective approach to drug development, reducing the need for early-stage human trials and improving decision-making throughout the process. in silico and drug development

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Genewity is a biotech company developing autologous cell and gene therapies.

306 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

352 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

626 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Applying AI to drug discovery Evariste is an AI-enabled drug discovery company developing small molecule inhibitors of next generation synthetic lethality targets. Using our automated AI-enabled drug discovery platform, Frobenius, we are able to progress preclinical drug discovery projects at scale and with unparalleled efficiency. Technology , Software, Biotech, Research, and Drug Discovery

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Getting therapeutic proteins where they are needed most, in the CNS and beyond. Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology designed to deliver potent therapeutic proteins beyond the human blood-brain barrier.

89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

584 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

237 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

90 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

702 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

we develop for patients Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

126 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology